Development of Online Hybrid Testing

Dr. Wang obtained an MD from Norman Bethune University of Medical Sciences in China, a PhD in Toxicology from University of Louisiana, and is a Diplomat of the American Board of Toxicology. Dr. Wang's professional experience includes clinical practice in oncology, research on gene regulation in an academic setting, and more than 20 years of professional practice as toxicologist in the pharmaceutical/biotech industry. She is currently the Executive Director of Translational & Development Sciences at Coherus BioSciences, where she oversees preclinical development (in vivo pharmacokinetics, pharmacology and toxicology of small molecules and biologics) of drug candidates from early through late stage development. Prior to joining Coherus, Dr. Wang worked at Novartis Pharmaceuticals and Achaogen, where she led safety assessment efforts for oncology and non-oncology drug development. Dr. Wang received multiple professional awards, recognizing her significant achievements and performance above and beyond work requirements (e.g. Novartis Above & Beyond, Due Diligence, Catalyst Awards, and Spot Awards). She was also acknowledged for outstanding collaboration and contributions on multidisciplinary teams (e.g., Novartis Team Award). Dr. Wang is an active member with Society of Toxicology (SOT), and has contributed to the society's leadership team as a Councilor and by serving on numerous elected and appointed committees. She also served on the Board of Directors for the American Board of Toxicology (ABT) and is an advisor to the Education Committee at International Union of Toxicology (IUTOX). Dr. Wang is on the Editorial Boards of the International Journal of Toxicology and Toxicology Research and Application. Dr. Wang has taught a course on Practical Toxicology at the University of California at Berkeley as a guest lecturer.